Impact of adjuvant chemotherapy for gliomatosis cerebri by Kong, Doo-Sik et al.
RESEARCH ARTICLE Open Access
Impact of adjuvant chemotherapy for gliomatosis
cerebri
Doo-Sik Kong
1†, Sung Tae Kim
2†, Jung-Il Lee
1, Yeon-Lim Suh
3, Do Hoon Lim
4, Won Seog Kim
5, Ki-Hoon Kwon
1,
Kwan Park
1, Jong Hyun Kim
1, Do-Hyun Nam
1*
Abstract
Background: Gliomatosis cerebri (GC) is characterized by a diffuse infiltration of tumor cells throughout CNS,
however, few details are available about the chemotherapeutic effect on GC. The aim of this study was to
investigate its clinical course and to determine the efficacy of chemotherapy for GC.
Methods: Between Jan. 1999 and Dec. 2004, 37 GC patients were diagnosed by biopsy and treated with
radiotherapy in a single institution. To determine the efficacy of chemotherapy for GC, we retrospectively reviewed
their clinical courses. The study cohort was divided into 2 groups, those with and without receiving post-
radiotherapy adjuvant chemotherapy such as temozolomide or nitrosourea-based chemotherapy.
Results: Nineteen patients with adjuvant chemotherapy were assigned to the chemotreatment group and 18 with
radiotherapy alone were assigned to the control group. Mean survival for chemotreatment group and control
group were 24.2 and 13.1 months, respectively (p = 0.045). Time to progression for these groups were 16.0 and 6.0
months, respectively (p = 0.007). Overall review of the clinical course of patients with GC provided that early
appearance of new contrast-enhancing lesions within 6 months from the initial diagnosis and higher histological
grade were closely associated with poor survival (p < 0.001 and p = 0.008).
Conclusion: Adjuvant chemotherapy following radiotherapy could prolong the survival in patients with GC. In
addition, newly developed contrast-enhanced lesions on the follow-up MR images indicate the progression of GC.
Background
Gliomatosis cerebri (GC) is a rare variant of glioma. It is
characterized by a diffuse infiltration of malignant glial
cells throughout large regions of the central nervous
system [1-6] and a relative preservation of the neural
architecture. Since Nevin first used the term gliomatosis
cerebri in 1938, describing the histological finding of
glial overgrowth of the brain [7], the World Health
Organization now defines GC as a diffuse glial tumor
that extensively infiltrates the brain and involves more
than multiple lobes (frequently bilaterally) [8]. Jennings
et al. reported that GC can be divided into two forms
based on descriptive neuropathological grounds [9,10].
Type I GC consists of well-differentiated low-grade glio-
mas without contrast enhancement and its clinical
course is often mild, with slow progression. Once the
tumor begins to progress and cancerous dedifferentia-
tion is observed, this type of tumor is referred to as type
II GC, leading to clinical deterioration.
In the treatment of GC, radiotherapeutic effects as the
first-line treatment have been supported by several stu-
dies [3,6,7,11]. However, chemotherapeutic effects as an
adjuvant treatment or first-line treatment are not defi-
nitely proved yet [10,12,13]. Here, we present a series of
37 GC patients who underwent radiotherapy for GC. To
identify the efficacy of adjuvant chemotherapy for GC,
we analyzed and compared clinical outcome between
adjuvant chemotherapy group and radiotherapy alone
group.
Methods
Including criteria
We retrospectively identified 45 consecutive patients
diagnosed with GC who were examined at a single insti-
tution between Jan. 1999 and Dec. 2004. Of these,
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any medium, provided the original work is properly cited.37 patients were included in this study based on the fol-
lowing criteria: 1) MRI evidence of diffuse, increased
signal intensity on the T2-weighted or FLAIR images
accompanied by a low or absent signal in the affected
areas on T1 images, 2) lesions involving more than two
cerebral lobes, 3) available serial MR images and clinical
follow-up data, 4) who underwent radiotherapy for GC.
Eight patients were excluded because of unavailable fol-
low-up data or no treatment history. To rule out other
inflammatory diseases, 24 patients underwent stereotac-
tic biopsy and 13 patients did partial tumor resection
immediately after radiological diagnosis. Information
about treatment response was obtained by reviewing the
patients’ radiological data and clinical medical records.
Immediately after surgery, local radiotherapy was per-
formed in all patients. The extent of the radiotherapy
was determined by the area of tumor involvement. A
median 5800 cGy (5400-6000 cGy) were delivered
according to routine treatment plans. The study was
approved by the local ethic committee.
Patients characteristics
The chemotreatment group received adjuvant TMZ or
nitrosourea-based chemotherapy following radiotherapy
(n = 19), and the control group underwent radiotherapy
alone (n = 18). There were no statistically significant
differences in baseline characteristics between the 2
groups (Table 1). For this cohort group, twenty-two
patients were men (59.5%) and 15 patients were women
(40.5%). The mean age at presentation was 41.2 years
(range: 11-67 years). The median KPS at the time of
initial diagnosis was 80 (range: 70-100). The MR images
demonstrated a variety of findings including presence of:
a dominant mass formation (18 cases) or a diffuse infil-
tration pattern (19 cases), initial dimly enhanced lesions
or not (6 vs. 31 cases), brainstem involvement or not
(11 vs. 26 cases), and tumor extent, i.e., involving two
lobes or ≥ 3 lobes (13 vs. 24 cases). Based on the histo-
pathological data, 23 patients were diagnosed as having
at u m o rw i t hl o w - g r a d ef e a t u r e s( g r a d eI I )a n d1 4
patients were diagnosed as having tumor with high-
grade features (grade III).
Adjuvant chemotherapy
19 of 37 patients (51.4%) received adjuvant chemother-
apy after radiotherapy, while 18 other patients under-
went local radiotherapy alone. Chemotherapeutic
regimens included temozolomide (TMZ) (200 mg/m
2
× consecutive 5 days per month, 3-9 cycles) and nitro-
sourea-based chemotherapy such as BCNU (carmus-
tine-[1,3-bis (2-chloroethyl)-1-nitrosourea]), PCV
(procarbazine/lomustine/vincristine). The choice of
Table 1 Characteristics of the patients with gliomatosis cerebri
Variable Chemotreatment group (n = 19) Control group (n = 18) P
Age 0.579
Median 44.4 43.5
range 13-58 11-67
Gender 0.638
Male 12 10
Female 7 8
KPS score 0.713
≥ 70 16 15
<7 0 3 3
Grade 0.420
Low 13 10
High 6 8
Mass formation 0.738
Dominant mass 9 9
Diffuse infiltration 10 9
Brainstem involvement 0.717
Yes 6 5
No 13 13
Hemisphere involvement 0.654
Unilateral 11 11
Bilateral 8 7
Operation 0.823
Biopsy 12 12
Partial tumor removal 7 6
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much tumors had oligodendroglial components. At an
earlier period, PCV chemotherapy was given for 5
patients with tumor which dominantly contained oligo-
dendroglial components, while BCNU treatment
(4 patients) was performed for tumors with dominant
astrocytic components. However, since TMZ treatment
had been widely introduced into our institution in
2002, 10 patients received TMZ treatment regardless
of the cellular components.
All patients were assessed by serial MR images with
contrast enhancement. The follow-up images were eval-
uated for progression versus no progression by a radiol-
ogist (Kim ST) blinded to the pathological and clinical
findings. During the follow-up period, we sometimes
observed new contrast-enhancing lesions, which had
been absent in the previous studies. These contrast-
enhancing lesions were patched or punctuated lesions
[14,15] and located in the mid-portion of widely infil-
trated lesions on FLAIR images. They could be differen-
tiated from radiation necrosis by several MR sequences
(diffusion/perfusion weighted images, MR spectroscopy,
or FDG-PET) [16-20]. It was difficult to apply the
tumor response criteria commonly used for high-grade
gliomas because of the lack of discrete and measurable
tumor margins. Tumor progression was assessed by
semi-quantitative analysis of the tumor extent in T2-
weighted or FLAIR-weighted MR images using commer-
cially available image analysis software (SCION Corp.).
In cases of tumor recurrence or progression, we per-
formed surgical resection of the enhancing lesions in 10
patients or gamma knife radiosurgery in 6 patients. All
patients with tumor recurrence or progression received
2
nd-line chemotreatment.
Statistical analysis
Overall survival and progression-free survival were cal-
culated using the Kaplan-Meier method and groups
were compared with the log-rank test. For statistical
analysis, age, gender, KPS, histological grade, degree of
resection, and involvement of brainstem were compared
using Fisher exact test or Mann-Whitney test between
the chemotreatment group and the control group. The
Cox proportional hazards model with a stepwise proce-
dure was used in the multi-variate survival analysis to
assess the prognostic factors for survival. P values of less
than 0.05 were considered statistically significant for all
tests, using the SPSS software (SPSS version 10.0, Chi-
cago, IL).
Results
During the follow-up period, median time to new
appearance of contrast-enhancing lesions was 12.0
months (95% CI: 7.7-16.3 months). In particular, early
appearance of new contrast enhancing lesions within
6 months was found in 11 of the 37 patients (29.7%). In
most cases, these patched or punctuated lesions were
developed in the small area of overall tumor involve-
ment at the initial stage and were strongly enhanced
with the contrast dye (Fig. 1). Overall review of clinical
course demonstrated that early appearance of new con-
trast enhancing lesions within 6 months was closely
related to poor survival (p < 0.001 by log-rank test).
Furthermore, early appearance of new enhancing lesions
within 6 months was also a significant independent vari-
able for tumor progression (p < 0.001 by log-rank test).
Treatment outcome
Twenty-five patients were still alive at the time of this
analysis and the median follow-up period was 12.6
months (range: 7.1-49.4 months). Median overall survi-
val in the chemotreatment group was 24.2 months (95%
CI: 23.4-24.9 months), compared with 13.1 months (95%
CI: 10.4-15.9 months) in the control group. Kaplan-
Meier analysis showed that median overall survival in
the chemotreatment group was longer than that in the
control group (p = 0.045 by log-rank test, Fig. 2). Age,
gender, KPS, cellular components, degree of resection
and brainstem involvement were not identified as inde-
pendent prognostic variables. For Cox proportional
hazard model, no chemotherapy (HR 6.385, 95% CI: 1.8-
22.6, p = 0.004) was strongly associated with poor survi-
v a le v e na f t e ra d j u s t m e n tf o ra g e ,s e x ,K P S ,c e l l u l a r
components, and brainstem involvement. Higher histo-
logical grade (HR 4.434, 95% CI: 1.312-14.982, p =
0.017) was also associated with dismal prognosis (table
2). Between patients treated with TMZ and those with
nitrosourea-based chemotreatment, there was no signifi-
cant difference of survival (p > 0.05 by log-rank test).
Median progression-free survival in the chemotreat-
ment group was 16.0 months (95% CI: 11.7-20.2
months), compared with 6.0 months (95% CI: 4.9-7.1
months) in the control group. Adjuvant chemotherapy
(OR 8.250, 95% CI: 1.8-38.7, p = 0.007 by log-rank test,
Fig. 3) was a significant independent factor for progres-
sion after adjustment of age, sex, KPS, cellular compo-
nents, and histological grade.
Discussion
Progression of GC: significance of the newly developed
contrast-enhanced lesion
GC is an infrequent and controversial diagnosis, because
the definition and pathophysiology have not been accu-
rately defined yet. Recent studies using antemortem
diagnostic criteria by MRI have revealed that the prog-
nosis for GC is generally poor and the overall survival
relatively short [1,2,6,8,9,21-27]. In the respective of
r a d i o l o g i c a lv i e w ,1 9o f3 8p a t i e n t si nt h i ss t u d yc o u l d
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others resulted from the spreading of a focal glioma
(secondary GC) [10]. Vates et al. suggested that GC
begins as either a low- or high-grade neoplasm without
a focal mass, which progresses to form a focal mass
similar to the natural history of low grade glioma [11].
However, GC should not be diagnosed by histopatholo-
gical finding, but by radiographic findings. Furthermore,
in most cases, difficulties in interpreting histological spe-
cimen are attributable to scattering of tumor cells and
small amount of tissue specimens obtained by stereotac-
tic biopsy. Therefore, it was too difficult to clarify the
specific histological types (astrocyte-dominant or oligo-
dendroglial-dominant) based on the tissue specimen. In
this study, an interval between early stage and tumor
progression in GC was extremely variable in each other.
We speculated that this change of enhancement pat-
tern might imply a malignant progression of GC. In the
current study, we found that early appearance of new
Figure 1 Serial MR images of gliomatosis cerebri. Case 2: (A & B) at the initial presentation, highly infiltrated lesion is found on the FLAIR
image, but there is no enhancing lesion on the T1 weighted enhanced image (T1WI), (C & D) After 3 months, the tumor is widely spread on
the FLAIR images and new contrast-enhancing lesions diffusely appears on the T1WI.
Figure 2 Comparison of overall survival between patients
treated with adjuvant chemotherapy plus radiotherapy
(chemotreatment group) and those with radiotherapy alone
(control group).
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correlated with the poor survival and tumor progression.
As a result, these findings supported that malignant
transformation of GC is similar to that of low-grade
gliomas. Tumor progression of GC used to be more
rapid than that of low-grade gliomas, which can be
explained by the following hypotheses. GC may contain
highly invasive stem-like tumor cells and therefore
shows a tendency to involve more lobes and progress
rapidly [28]. Otherwise, it can be interpreted as a trans-
formation from angiogenesis-independent growth to an
angiogenesis-dependent phenotype driven by stem-like
cells [29]. In the future, a detailed review of the clinical
course in GC will contribute to our understanding of
malignant progression of tumors [30].
Therapeutic effects of adjuvant chemotherapy for GC
To date, little is known about the therapeutic effect of
adjuvant chemotherapy for GC. However, some
researchers demonstrated that upfront TMZ treatment
was effective for patients with GC [10,12,13]. By using a
retrospective case-cohort study, we investigated the effi-
cacy of adjuvant chemotherapy such as TMZ or
nitrosourea-based chemotherapy for GC. In this study,
we demonstrated that adjuvant chemotherapy following
radiotherapy was effective for the prolongation of survi-
val and delay of tumor progression. This suggests that
adjuvant chemotherapy as well as first-line chemother-
apy also provide improvement of survival in patients
with GC. Furthermore, multivariate analysis revealed
that GC patients with higher histological grade had
shorter survival and earlier tumor progression than
those with lower histological grade. Therefore, during
the follow-up period, higher histological grade at the
initial presentation or earlier appearance of enhance-
ment should warrant dismal prognosis.
However, it is not certain that adjuvant chemotherapy
should be required following radiotherapy for GC,
because this retrospective study has some drawbacks.
Even though these two groups were relatively balanced
with respect to known prognostic variables, they were
not randomly-allocated groups, but were groups deter-
mined by physician’s preference. We should recognize
that these selection biases could account for its effect on
survival. Moreover, it was another important limitation
in this study that chemotreatment group was composed
of heterogeneous populations, for example, those treated
with TMZ or nitrosourea-based chemotherapy.
Conclusion
In conclusion, adjuvant chemotherapy following radio-
therapy could prolong the survival in patients with GC.
In addition, newly developed contrast-enhanced lesions
on the follow-up MR images indicate the progression
of GC.
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